Patent 5961970 Issued on October 5, 1999. Estimated Expiration Date: April 29, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
424/93.1, WHOLE LIVE MICRO-ORGANISM, CELL, OR VIRUS CONTAINING424/184.1, ANTIGEN, EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR (E.G., IMMUNOSPECIFIC VACCINE, IMMUNOSPECIFIC STIMULATOR OF CELL-MEDIATED IMMUNITY, IMMUNOSPECIFIC TOLEROGEN, IMMUNOSPECIFIC IMMUNOSUPPRESSOR, ETC.)424/278.1, NONSPECIFIC IMMUNOEFFECTOR, PER SE (E.G., ADJUVANT, NONSPECIFIC IMMUNOSTI- MULATOR, NONSPECIFIC IMMUNOPOTENTIATOR, NONSPECIFIC IMMUNOSUPPRESSOR, NON- SPECIFIC IMMUNOMODULATOR, ETC.); OR NONSPECIFIC IMMUNOEFFECTOR, STABILIZER, EMULSIFIER, PRESERVATIVE, CARRIER, OR OTHER ADDITIVE FOR A COMPOSITION CON- TAINING AN IMMUNOGLOBULIN, AN ANTISERUM, AN ANTIBODY, OR FRAGMENT THEREOF, AN ANTIGEN, AN EPITOPE, OR OTHER IMMUNOSPECIFIC IMMUNOEFFECTOR424/279.1, Synthetic or structurally-modified peptidoglycan or mucopolysaccharide or fragment thereof (e.g., derivative of N-acetyl-muramyl-L-alanyl-D-glutamic or fragment thereof (e.g., derivative of N-acetyl-muramyl-L-alanyl-D- acid, etc.) glutamic acid, etc.)424/283.1, Lipid or oil424/450, Liposomes424/452, With claimed designated perfecting feature in contents (e.g., excipient, lubricant, etc.)424/455, Containing emulsions, dispersions, or solutions424/462, Containing solid synthetic polymers424/490Coated (e.g., microcapsules)
A vaccine adjuvant composition of an oil-in-water submicron emulsion that has about 0.5 to 50% of a first component of an oil, about 0.1 to 10% of a second component of an emulsifier, about 0.05 to 5% of a nonionic surfactant, about 0.00001 to 1% of an immunogen, and an aqueous continuous phase. This submicron emulsion has a mean droplet size in the range of between about 0.03 and 0.5 μm, and preferably 0.05 and 0.2 μm.
Other References
Journal of Immunological Methods, 135 (1990) 101-109 "Preparation of protome-baseed vaccines Correlation of immunogenicity with physical characteristics", by Curtis L. Ruegg et al
The Journal of Immunology, vol. 140, 1274-1279, No. 4, (1988), "Effective Immunization Against Cutaneous Leishmaniasis With Defined Membrane Antigens Reconsituted Into Liposomes", by David G. Russell
Analytical Biochemistry 211, 117-122 (1993), "Lyophilized Liposomes as Shelf Items for the Preparation of Immunogenic Liposome-Peptide Conjugates" by M. Friede
J. Pharm. Pharmacol, (1985), 37: 134-136, "Enhancement of nasal absorption of insulin and clacitonin using polyacrylic acid gel" by Kazuhiro Morimoto
Pharmaceutical Research, vol. 9, No. 12, 1992, "Mucoadhesion of Copolymers and Mixtures Containing Polyacrylic Acid" by Florence Thermes et al
Infection and Immunity, Jun. 1993, pp. 2390-2395, "Immunogenicity and Efficicay of Oral or Intranasal Shigella Flexneri 2a and Shigella sonnei Proteosome-Lipopolysaccharide Vaccines in Animal Models" by Nadav Orr et al
Infection and Immunity, Sep. 1991, pp. 2978-2986, "Biodegradable and Biocompatible Poly(DL-Lactide-Co-Glycolide) Microspheres as an Adjuvant for Staphylococcal enterotoxin B Toxoid Which Enhances the Level of Toxin-Neutralizing Antibodies" by John H. Eldrige et al
Immunology 1991, 72: 3-9, "Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (gp63) from Leishmania major", by D.M. Yang et al
Journal of Experimental Medicine, vol. 167, 1988, 658-663, "Peptides Bound To Proteosomes Via Hydrophobic Feet Become Highly Immunogenic Without Adjuvants" by George H. Lowell et al
Biotechnology Therapeutics, 2(1-2--, 91-106 (1990-1991), "Characterization of a Vaccinia-Derived recombinant HIV-1 gp160 Candidate Vaccine and Its Immunogenicity in Chimpanzees" by N. Barrett et al
CRC Press, Inc., Liposome Technology, 2nd Edition, vol. 1, Chapter 28, p. 501, Liposome Preparation and Related Techniques, edited by Gregory Gregoriadis, Ph.D., "A Large-Scale Method For The Preparation Of Sterile And Nonpyrogenic Liposomal Formulations Of Defined Size Disbributions For Clinical Use", Shimon Amselem, Alberto Gabizon, and Yechezkel Barenholz
Methods of Biochemical Analysis, vol. 33, D. Glick, editor, J. Wiley & Sons, N.Y., 1988, "Liposomes: Preparation, Characterization, and Preservation", Dov Lichtenberg and Yechezkel Barenholz
Journal of Pharmaceutical Sciences, vol. 79, No. 12, Dec. 1990, "optimization and upscaling of Doxorubicin-Containing Liposomes for Clinical Use", S. Amselem, A. Gabizon and Y. Barenholz
CRC Press Inc., 1993, Liposome Technology 2nd Ed., edited by G. Gregoriadis, PhD., vol. 1, Chapter 3, p. 49, "Liposome Preparation Using High-Pressure Homogenizers", Martin M. Brandl, Dieter Bachmann, Markus Dreschsler, and Kurt H. BauerElsevier Science Publishers B.V. (Biomedical Division, 1986,, Laboratory Technology in Biochemistry and Molecular Biology, vol. 3, part 2, edited by R.H. Burdon and P.H. van knippenberg, "Techniques of Lipidology--Isolation, Analysis and Identification of Lipis", 2nd revision editio, Moris Kates
April 29, 2016. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
